Intrommune Therapeutics Presents Supporting Data Introducing a New Form of Food Allergy Treatment
February 22, 2024 09:34 ET
|
Intrommune Therapeutics
OMIT (Oral Mucosal Immunotherapy) is a new approach to the management of food allergy demonstrating a robust immunologic response in treated subjects
Bioxytran’s Oral Antiviral Drug to Enter Dose Optimization Clinical Trial for COVID-19
February 21, 2024 08:00 ET
|
BIOXYTRAN, INC.
First Medicinal chemistry of an antiviral drug made of sugars BOSTON, MASSACHUSETTS, Feb. 21, 2024 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC. (OTCQB: BIXT), (the “Company”), a clinical stage biotechnology...
Omnix Medical Granted Fast-Track Designation by U.S. FDA for its Next-Generation Anti-Infective OMN6
February 20, 2024 04:00 ET
|
AKAMPION
- Designation underlines the need for novel, first-in-class antimicrobials for the treatment of infections with Gram-negative bacteria JERUSALEM, Israel, February 20, 2023 -- Omnix Medical, a...
Vaccinex, Inc. Announces Reverse Stock Split
February 15, 2024 08:00 ET
|
Vaccinex, Inc.
ROCHESTER, N.Y., Feb. 15, 2024 (GLOBE NEWSWIRE) -- Vaccinex, Inc., (NASDAQ: VCNX), a clinical-stage biotechnology company pioneering a differentiated approach to treating neurodegenerative disease...
Theratechnologies complète le recrutement des six premières patientes de l’essai clinique de phase I mis à jour sur le sudocétaxel zendusortide dans le traitement du cancer de l’ovaire avancé
February 15, 2024 07:30 ET
|
Theratechnologies
Une étape importante de l’étude afin de poursuivre l’élan pour le principal CPM de la Société et son programme de développement clinique en oncologie MONTRÉAL, 15 févr. 2024 (GLOBE...
Theratechnologies Completes Enrollment of First Six Patients in Updated Phase 1 Clinical Trial of Sudocetaxel Zendusortide in Advanced Ovarian Cancer
February 15, 2024 07:30 ET
|
Theratechnologies
Study milestone further extends momentum for Company’s lead PDC candidate and oncology clinical development program MONTREAL, Feb. 15, 2024 (GLOBE NEWSWIRE) -- Theratechnologies Inc....
Cybrexa Regains Rights to CBX-12
February 06, 2024 08:00 ET
|
Cybrexa Therapeutics
NEW HAVEN, Conn., Feb. 06, 2024 (GLOBE NEWSWIRE) -- Cybrexa Therapeutics, a clinical-stage oncology biotechnology company developing a novel class of tumor-targeting peptide drug conjugate (PDC)...
Thermosome Announces Further Dose Escalation in Phase I Trial with Lead Program THE001
February 06, 2024 04:00 ET
|
AKAMPION
- First dose level rated as safe by independent Data Safety Monitoring Board- Second dose level to be administered according to plan- THE001 designed as targeted tumor treatment independent...
HilleVax to Present at Guggenheim 6th Annual Biotechnology Conference
February 05, 2024 16:05 ET
|
HilleVax, Inc.
BOSTON, Feb. 05, 2024 (GLOBE NEWSWIRE) -- HilleVax, Inc. (Nasdaq: HLVX), a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines, today announced that it...
MetrioPharm veröffentlicht Studiendaten, die die Wirkung einer Host-Directed Therapy in COVID-19 zeigen
January 31, 2024 05:00 ET
|
AKAMPION
Ergebnisse stammen aus der klinischen Studie CT-05 an 131 hospitalisierten Patienten mit COVID-19Die Daten zeigen, dass MetrioPharms Leitsubstanz MP1032 eine mit Remdesivir vergleichbare Wirksamkeit...